The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the biotech investment landscape..| Evaluate
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […] The post Three Things we Learned in our World Preview 2025 Webinar appeared first on Evaluate.| Evaluate
The World Preview webinar will include many data highlights from the report as well as discussion of the big themes in the market.| Evaluate
The board at Verona Pharma was taking the steps necessary to take its chronic obstructive pulmonary disorder (COPD) drug to market years ahead of its launch in 2024. This long term view was one of the details shared by Verona’s Chief Commercial Officer, Chris Martin during our recent webinar “Going Solo: What’s Driving the Biotech […] The post Three Things we Learned in our Biotech Commercialization Webinar appeared first on Evaluate.| Evaluate
“Think twice, and twice more, before launching your own drug. It is unimaginably difficult and complex”. Those were the words of a biotech CEO I interviewed more than a decade ago. The advice remains sound. Yet today there are tailwinds encouraging more biotechs to take their prized assets all the way to market. (And let’s […] The post A Blueprint for Biotech Commercialization? appeared first on Evaluate.| Evaluate
Discover 3 key insights from our webinar on first to market advantage in the pharma industry. Learn how these findings can impact your portfolio strategy.| Evaluate
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […] The post Should Pharma Companies Really Race to be First to Market? appeared first on Evaluate.| Evaluate
In our webinar about long-range planning processes in pharma we looked at the foundational pieces you need to achieve accurate forecasts| Evaluate
Having good forecast models is critical for effective and efficient decision-making. This will deliver accurate and reliable insights to help support business objectives and drive brand or company growth, highlight risk, and quantify opportunity. This article explores the key ingredients needed for developing good pharmaceutical forecast models. It’s widely accepted that there is no such […] The post What makes a good (and bad) pharmaceutical forecast model appeared first on Evaluate.| Evaluate
No element of pharmaceutical forecasting is easy but there’s a particular challenge in long-range planning. The range of components involved results in a greater degree of complexity which can allow inaccuracies to creep in very easily. We covered some of the key challenges in a recent webinar, The Forecaster’s Guide to Long-Range Planning, which you […] The post How can you Improve Efficiencies in your Long-Range Planning? appeared first on Evaluate.| Evaluate
Our recent orphan drugs webinar provided a wealth of insights into the current state and future of the orphan drug market. It was based on our annual report (which is available here) and if you missed it, I recommend taking the time to watch the on-demand version. Our panel included the report’s author, Melanie Senior […] The post Three Things We Learned in Our Orphan Drugs Webinar appeared first on Evaluate.| Evaluate
Evaluate produces some really valuable reports, webinars and articles that provide insight about the pharma market. Find the latest here.| Evaluate
If you follow Evaluate’s regular white papers and blogs, you may be familiar with our annual report that investigates the state of the orphan drug market. I’ve been involved in analyzing that data for the past three years, and have just finished the process for this year’s report which will be published soon. One of […] The post Is it Time to Rethink Orphan Drugs? appeared first on Evaluate.| Evaluate
Enhance your forecasting expertise with J+D's training programs. Boost confidence and skills through self-assessment, tailored courses, and real-world applications.| Evaluate
In our long-range planning in pharma webinar, we looked at the challenges and best practices to ensure successful 5-10 year forecasts.| Evaluate
Once again, the pharma industry starts a new year with hopes of a recovery. Will 2025 finally see a return of IPOs? Of mega-mergers? Of huge rounds of investment? Perhaps, but more likely this year will simply be a few steps in the right direction. There is still a great deal of uncertainty, particularly around […] The post What Will 2025 Hold for Pharma? appeared first on Evaluate.| Evaluate
Obesity. The Inflation Reduction Act. Orphan Drugs. CDMOs. Successful forecasting techniques. We’ve covered all this and more in our biopharma reports, webinars and analysis throughout 2024. As I’ve had the pleasure of working with our experts to create all this content, I thought year-end was a splendid opportunity to share the most-read pieces of the […] The post Biopharma Reading List: The Evaluate Top 10 of 2024 appeared first on Evaluate.| Evaluate
Picture the scene. You’ve got a new, hugely promising new drug in the pipeline and all the clinical signs are looking good. Which means you have to start focusing on your launch strategy to ensure commercial success. You need to refine your list of potential opportunities and threats, and develop forecasts that will ensure the […] The post Three Things we Learned in our Launch Excellence Webinar appeared first on Evaluate.| Evaluate
One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […] The post Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar appeared first on Evaluate.| Evaluate
At the recent CPHI exhibition in a very wet Milan, you couldn’t move for booths expounding on the capabilities of the world’s manufacturing, services, packaging and ingredients players. Some of these companies formerly considered themselves to be Contract Research Organisations (CROs) or CMOs (Contract Manufacturing Organisations) but now proudly display the letters CDMO (Contract Development […] The post CDMOs: A Paradigm Change for Pharma? appeared first on Evaluate.| Evaluate
Launching a first-in-class drug is high on the wish list of most pharma companies, but achieving that goal is not without its challenges. While patient demand for innovative therapies will always be high, modelling their impact on the treatment landscape is an uncertain business and the stakes are too high to rely on little more […] The post Analogue forecasting: the power of the past to predict the future appeared first on Evaluate.| Evaluate
BIO-Europe took place last week in Stockholm. It’s one of the last big biopharma events of the year and a great time to take stock of where the industry stands as the new year approaches. I was at the convention, taking part in a fireside chat to discuss global innovation trends. Also featuring on the […] The post Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma appeared first on Evaluate.| Evaluate
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re back, though, you’ll be delighted to know that it’s available on demand so you can catch up at your leisure. Our panel, which included Daniel […] The post In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar appeared first on Evaluate.| Evaluate
You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t cover everything in the report. However, that’s what webinars are for! I’m delighted to be taking part in Evaluate’s upcoming webinar which will explore the […] The post Orphans are Getting Strategic appeared first on Evaluate.| Evaluate
2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028. Perhaps as much as 6% of the nearly $1.6 trillion overall drug market might be at risk and while this isn’t Big […] The post What’s the Deal? Navigating the Complex World of Pharma Business Development appeared first on Evaluate.| Evaluate
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […] The post Orphan Drug Report 2024: Slowdown a Sign of Success appeared first on Evaluate.| Evaluate
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need regular topping up to ensure companies can deliver long-term growth in the face of new competition, and loss of exclusivity. At Evaluate, we work closely […] The post Next Generation Dealmaking with Evaluate and Inpart appeared first on Evaluate.| Evaluate
You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […] The post In Case You Missed It: Three Things We Learned In Our World Preview Webinar appeared first on Evaluate.| Evaluate
All parts of the pharma ecosystem are touched by speculation about AI. From drug discovery to clinical trials.| Evaluate
Missed our World Preview webinar? Check it out on-demand to get the highlights from our panel as they discuss the latest pharma forecasts.| Evaluate
Forecasting serves to help pharmaceutical companies identify market opportunities and risks, particularly when taking a sales-based approach.| Evaluate
Good pharmaceutical forecasting requires robust processes to comply with best practices and create accurate results. Find out what the processes are.| Evaluate
Over the last 10 years, large pharma companies have spent an average of $120bn across pharma R&D and business development investments.| Evaluate
Our World Preview report features pharma forecasts out to 2030. The theme this year is “Pharma’s Growth Boost”.| Evaluate
Missed our webinar on orphan drugs? Catch up on the discussion with experts Melanie Senior, Puru Gaur, and Stephanie Léouzon on demand.| Evaluate
Empower your pharmaceutical forecasting with FC365. Streamline processes, save time, and enhance efficiency with our pharma-specific SaaS platform.| Evaluate
Neurology is experiencing a revival with notable clinical advancements and increased deal activity from pharmaceutical giants.| Evaluate